Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 XOMA Forms Pact With Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

XOMA Forms Pact With Novartis

Relates to first-in-class anti-TGF-beta antibody program in immuno-oncology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

XOMA Corporation has licensed the global development and commercialization rights to its anti-transforming growth factor-beta (TGFb) antibody program to Novartis. XOMA will receive $37 million upfront and is eligible to receive up to $480 million if all development, regulatory, and commercial milestones are met. In addition, XOMA is eligible to receive royalties on product sales that range from the mid-single digits to the low double digits.

“XOMA and Novartis have worked closely together for several years to develop new product candidates. When they expressed interest in ouranti-TGFb program, we knew Novartis was the best company to bring this exciting potential therapy to the patients whom it may help,” said John Varian, chief executive officer, XOMA. “Novartis is recognized as a leader in oncology, where an anti-TGFb molecule has real potential either as monotherapy or in combination with other therapeutic options.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters